This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: Merck Serono S. a.. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Sonia Schnieper-Samec: Innovator in Genetic Markers for Growth Hormone Therapy
Introduction
Sonia Schnieper-Samec is a prominent inventor based in Geneva, Switzerland. She has made significant contributions to the field of genetics, particularly in the context of growth hormone therapy. Her work focuses on identifying genetic markers that can predict patient responses to treatment, which is crucial for effective medical interventions.
Latest Patents
Sonia holds a patent for her invention titled "Genomic markers for prediction of long-term response to growth hormone (GH) therapy." This innovative patent relates to the use of genetic markers to identify the response to growth hormone treatment in patients with Growth Hormone Deficiency (GHD) or Turner Syndrome (TS). The invention also includes methods for treating GHD or TS patients and kits for genotyping. She has 1 patent to her name.
Career Highlights
Sonia is currently employed at Merck Serono S.A., a leading biopharmaceutical company. Her role involves extensive research and development in the field of genetic therapies. Her expertise and innovative approach have positioned her as a key figure in her area of specialization.
Collaborations
Throughout her career, Sonia has collaborated with notable colleagues, including Pascal Croteau and John Raelson. These partnerships have enhanced her research and contributed to the advancement of genetic therapies.
Conclusion
Sonia Schnieper-Samec is a trailblazer in the field of genetic research, particularly in the context of growth hormone therapy. Her innovative work continues to impact the lives of patients with GHD and TS, showcasing the importance of genetic markers in personalized medicine.